Cancer NetworkOriginal article
<![CDATA[Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes]]>
ConferencepositiveofirnoflastPositive
AI Analysis
Summary
Ofirnoflast demonstrated activity across high-risk mutated MDS subtypes, including TP53-mutant disease, according to data presented by Dr. David Sallman at SOHO 2026.
Clinical Trial Data
Outcome Details
Ofirnoflast demonstrated activity across high-risk mutated MDS subtypes, including TP53-mutant disease
Importance:5/10
Sentiment:
0.65
MDSTP53_mutationofirnoflastclinical_dataSOHO_2026
Read the original article
Published by Cancer Network on September 11, 2026 9:00 PM